Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
May 23, 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
May 22, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments...
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
May 20, 2024 06:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in...
Osten & Victor Alberta Tennis Centre launches Everyone Can Play Program to create inclusivity promoting tennis as a sport for everyone
May 15, 2024 14:15 ET
|
Osten & Victor Alberta Tennis Centre
CALGARY, Alberta, May 15, 2024 (GLOBE NEWSWIRE) -- Today, The Osten & Victor Alberta Tennis Centre (The ATC) held a press conference to announce the launch of its new Everyone Can Play program,...
Sportradar Reports First Quarter 2024 Financial and Operating Results
May 15, 2024 07:00 ET
|
Sportradar AG
Achieved Record Revenue of €266 Million, Up 28% and Grew Adjusted EBITDA 29% Raising 2024 Outlook for Revenue and Adjusted EBITDA Commencing Purchases Under Previously Announced Share Repurchase...
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 14, 2024 08:00 ET
|
Tenax Therapeutics
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF ...
Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Report 2024: USA Dominating with 5 Therapies, FDA Orphan Designation, Proprietary Development Technologies by Companies
May 14, 2024 05:38 ET
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering....
Alpha Odds da Sportradar Aumentou os Lucros em 15% para os Operadores nas Partidas Classificatórias da UEFA Euro 2024
May 13, 2024 03:20 ET
|
Sportradar AG
ST. GALLEN, Suíça, May 13, 2024 (GLOBE NEWSWIRE) -- A Alpha Odds da Sportradar (NASDAQ: SRAD), a tecnologia de probabilidades personalizadas baseada em IA aumentou os lucros dos operadores...
Sportradar’s Alpha Odds Increased Profits By 15% for Operators Across UEFA Euro 2024 Qualifying Matches
May 13, 2024 03:16 ET
|
Sportradar AG
ST. GALLEN, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Odds, Sportradar’s (NASDAQ: SRAD) AI-driven personalised odds technology, boosted profits for sportsbook operators by an average of...
iTeos meldet Finanzergebnisse für das erste Quartal 2024 und gibt aktuelle Geschäftsinformationen bekannt
May 11, 2024 13:31 ET
|
iTeos Therapeutics Inc.
- Belrestotug + Dostarlimab übertraf die vordefinierten Wirksamkeitskriterien für klinisch relevante Aktivität, die in einer Zwischenbewertung der Phase 2 von GALAXIES Lung-201 beobachtet wurde -...